Sonia F Raffe

Jan 17, 2024 | sti.bmj.com | Giovanni Villa |Drieda Zace |Sonia F Raffe

Pay-it-forward incentives as a strategy to increase hepatitis B and C testing in the communityPay-it-forward incentives involve offering a free test and then giving a chance to donate money to support testing of another anonymous person.

Oct 17, 2023 | sti.bmj.com | Weiming Tang |Sonia F Raffe |Marina Daskalopoulou

Sitafloxacin for rectal and urogenital infections with quinolone-resistant Mycoplasma genitaliumSitafloxacin is a fourth-generation fluoroquinolone approved in Japan. An open-label prospective study evaluated sitafloxacin monotherapy (200 mg daily for 7 days) for treating rectal and urogenital infections in 180 men who have sex with men (MSM, 72 living with HIV), including 97 of 126 (77%) and 27 of 120 (23%) carrying strains with mutations in parC and gyrA, respectively.

Oct 17, 2023 | sti.bmj.com | Weiming Tang |Sonia F Raffe |Marina Daskalopoulou

Sitafloxacin for rectal and urogenital infections with quinolone-resistant Mycoplasma genitaliumSitafloxacin is a fourth-generation fluoroquinolone approved in Japan. An open-label prospective study evaluated sitafloxacin monotherapy (200 mg daily for 7 days) for treating rectal and urogenital infections in 180 men who have sex with men (MSM, 72 living with HIV), including 97 of 126 (77%) and 27 of 120 (23%) carrying strains with mutations in parC and gyrA, respectively.